VJOncology is committed to improving our service to you

ASCO 2018 | PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer

VJOncology is committed to improving our service to you

Robert Coleman

Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficacy of 6-month vs. 12-month adjuvant trastuzumab use in patients with HER2+ early breast cancer. In this interview, Robert Coleman, MBBS, MD, FRCP, FRCPE, of the University of Sheffield, Sheffield, UK, discusses the results of this study and their wider implications.This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter